Confronto

Efinopegdutide vs. Petrelintide

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Metabolico

N. CAS

2055640-93-0

nessun dato

Peso molecolare

nessun dato

Emivita

115 h

nessun dato

Sequenza

modifiziertes, von Oxyntomodulin abgeleitetes Peptid, konjugiert an ein humanes IgG4-Fragment (Verlängerung der Plasma-Halbwertszeit)

nessun dato

Meccanismo d'azione

Efinopegdutide

Efinopegdutide is an oxyntomodulin-derived peptide acting as a dual agonist at the GLP-1 and glucagon receptors with a relative potency of approximately 2:1 (GLP-1 to glucagon). The GLP-1 component mediates glucose-dependent insulin secretion and modulation of satiety; the glucagon component increases energy expenditure and hepatic fat oxidation, which is proposed to contribute to the observed reduction in liver fat. Conjugation to an IgG4 fragment prolongs the half-life and enables weekly administration.

Petrelintide

As an amylin analogue, petrelintide acts through amylin receptors, promoting satiety and slowed gastric emptying — a satiety pathway independent of the GLP-1 axis.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Efinopegdutide	Petrelintide
Germania	Non approvato	Non approvato
Stati Uniti	Non approvato	Non approvato

Voci complete

Frequently asked questions

What is the difference between Efinopegdutide and Petrelintide?: Efinopegdutide is classified as "Metabolico", while Petrelintide is classified as "Metabolico". Efinopegdutide: Efinopegdutide (MK-6024, formerly JNJ-64565111 / HM12525A) is a once-weekly dual agonist at the GLP-1 and glucagon receptors, developed by Hanmi and Merck. It has been studied for obesity and notably for metabolic liver disease (MASH/NAFLD); a phase-2 trial showed greater liver-fat reduction than semaglutide. Investigational, not approved. Petrelintide: Petrelintide is a long-acting amylin analogue (Zealand Pharma, with Roche) for once-weekly subcutaneous use — developed for weight management with a focus on strong tolerability. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Efinopegdutide or Petrelintide?: The highest available evidence level is "RCT sull'uomo" for Efinopegdutide and "RCT sull'uomo" for Petrelintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Efinopegdutide and Petrelintide in Germany and the United States?: Germania: Efinopegdutide — Non approvato, Petrelintide — Non approvato. Stati Uniti: Efinopegdutide — Non approvato, Petrelintide — Non approvato. These are factual summaries with source and review date on the individual pages.

Country

Efinopegdutide

Petrelintide

Germania

Non approvato

Stati Uniti

Non approvato

Frequently asked questions

What is the difference between Efinopegdutide and Petrelintide?

Efinopegdutide is classified as "Metabolico", while Petrelintide is classified as "Metabolico". Efinopegdutide: Efinopegdutide (MK-6024, formerly JNJ-64565111 / HM12525A) is a once-weekly dual agonist at the GLP-1 and glucagon receptors, developed by Hanmi and Merck. It has been studied for obesity and notably for metabolic liver disease (MASH/NAFLD); a phase-2 trial showed greater liver-fat reduction than semaglutide. Investigational, not approved. Petrelintide: Petrelintide is a long-acting amylin analogue (Zealand Pharma, with Roche) for once-weekly subcutaneous use — developed for weight management with a focus on strong tolerability. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Efinopegdutide or Petrelintide?

The highest available evidence level is "RCT sull'uomo" for Efinopegdutide and "RCT sull'uomo" for Petrelintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Efinopegdutide and Petrelintide in Germany and the United States?

Germania: Efinopegdutide — Non approvato, Petrelintide — Non approvato. Stati Uniti: Efinopegdutide — Non approvato, Petrelintide — Non approvato. These are factual summaries with source and review date on the individual pages.